<DOC>
	<DOCNO>NCT00443495</DOCNO>
	<brief_summary>Chitin microparticles ( CMP ) demonstrate animal study model allergic rhinitis effective wide range common respiratory allergen . It immuneenhancer . The primary purpose study demonstrate safety first man study 24 human volunteer . The secondary objective demonstrate efficacy chosing subject demonstrate response nasal allergen challenge use grass pollen . The subject give increase dos CMP , supply nasal spray , 7 day follow nasal allergen challenge Timothy Grass Pollen extract . Over period nasal symptom score , eosinophil count cytokine measurement perform .</brief_summary>
	<brief_title>Phase I/IIa Study Chitin Microparticles Subjects Suffering From Allergic Rhinitis</brief_title>
	<detailed_description>Chitin microparticles special preparation chitin . This long chain polysaccaride derive shell North Atlantic shrimp . CMP act immunenhancer improve immune function stimulate macrophage cell T-helper lymphocyte , ( Th cell ) . In allergy imbalance Th1 Th2 cell . Imuneenhancers shift balance favour Th1 cell . The immunomodulatory property CMP demonstrate animal model wide range respiratory allergen . There indication toxic side effect animal model .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>1 . Males age 18 50 year age inclusive history symptom allergic rhinitis within previous two year . 2 . Subjects must free clinically significant cardiac , pulmonary , gastrointestinal , hepatic , renal , haematological , neurological psychiatric disease determine history , physical examination screen investigation . 3 . Forced expiratory volume one second ( FEV1 ) within normal limit ( ≥ 90 % predict , ECCS 1993 ) . 4 . Asymptomatic screen characterize : 1 . Normal appear nasal mucosa active allergic rhinitis . 2 . A prenasal allergen challenge total nasal symptom score sheet study entry subject produce score &lt; 2 screening . 5 . Non smoker least past 12 month pack history ≤ 1 pack year ( Pack year = ( n cigarette smoked/day/20 ) x n year smoke ) . 6 . An increase nasal symptom score 4 10 follow screen nasal allergen challenge . 7 . Capable give informed consent , include compliance requirement restriction list consent form . 8 . Available complete study . 9 . Negative urinary drug abuse screen , determine screen 24 hour first dose study medication . 10 . Negative carbon monoxide test ( smokerlyzer ) determine screen 24 hour first dose study medication . 11 . Clinically normal vital sign 12lead electrocardiogram ( ECG ) , determine screening . 12 . A body mass index ( Quetlet index ) range 18.00 30.9 . 1 . Perennial rhinitis . 2 . Upper respiratory tract infection within 2 week first dose study medication . 3 . Medical condition likely affect outcome study opinion investigator . 4 . Nasal condition likely affect outcome study opinion investigator , i.e . nasal septal perforation , nasal polyp , sinus disease , chronic nasal obstruction , nasal disease . 5 . Presence respiratory disease history mild stable asthma require treatment associate normal lung function ( define ≥ 90 % predict height age , ECCS 1993 ) . 6 . History immunotherapy past 3 year currently immunotherapy treatment course include inhaled local corticosteroid past 28 day . 7 . Any infirmity , disability , geographic location , opinion principal investigator , would limit compliance protocol . 8 . Infection upper airways/lower airway , sinus , ear , include viral infection 14 day prior screen start treatment period . 9 . Clinically significant abnormality clinical laboratory test screen determine principal investigator . 10 . Inability tolerate lavage correctly preliminary nasal lavage screening . 11 . Participation study new molecular entity previous four month trial previous three month . 12 . The subject regularly , average , drinks four unit alcohol per day . 13 . Testing positive hepatitis C antibody hepatitis B surface antigen HIV . 14 . Receipt prescribed counter medication ( include herbal remedy dietary supplement ) within 14 day first dose test article duration trial ( exception paracetamol 2g daily ) . In particular , antihistamine , chromoglycate steroid prohibit period . 15 . Inability communicate well investigator ( i.e. , language problem , poor mental development impair cerebral function ) . 16 . Donation 450 mL blood within previous 12 week . 17 . A history hypersensitivity and/or idiosyncrasy test compound excipients employ study . 18 . Subjects clinical feature suspicious tuberculosis – weight loss , pyrexia , haemoptysis , purulent sputum , previous abnormal chest Xray exclude study . 19 . Clinical evidence autoimmune disease . 20 . Allergy seafood .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2007</verification_date>
</DOC>